Balancing Safety, Effectiveness, and Public Desire: the FDA and Cancer
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95.
DOI: 10.1067/mcp.2001.113989.
View
2.
Smith M, Ho P
. Pediatric drug development: a perspective from the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). Invest New Drugs. 1996; 14(1):11-22.
DOI: 10.1007/BF00173678.
View
3.
Gelmon K, Eisenhauer E, Harris A, Ratain M, Workman P
. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?. J Natl Cancer Inst. 1999; 91(15):1281-7.
DOI: 10.1093/jnci/91.15.1281.
View
4.
Schein P
. The case for a new national program for the development of cancer therapeutics. J Clin Oncol. 2001; 19(12):3142-53.
DOI: 10.1200/JCO.2001.19.12.3142.
View
5.
Johnson J, Decker S, Zaharevitz D, Rubinstein L, Venditti J, SCHEPARTZ S
. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001; 84(10):1424-31.
PMC: 2363645.
DOI: 10.1054/bjoc.2001.1796.
View